Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Yen-Hua Huang
 + 1796 word(s) 1796 2021-03-17 04:34:06 |
2 format correct
Camila Xu
 Meta information modification 1796 2021-03-25 07:01:39 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Huang, Y. Hepatocellular Carcinomas. Encyclopedia. Available online: https://encyclopedia.pub/entry/8255 (accessed on 08 July 2024).
Huang Y. Hepatocellular Carcinomas. Encyclopedia. Available at: https://encyclopedia.pub/entry/8255. Accessed July 08, 2024.
Huang, Yen-Hua. "Hepatocellular Carcinomas" Encyclopedia, https://encyclopedia.pub/entry/8255 (accessed July 08, 2024).
Huang, Y. (2021, March 25). Hepatocellular Carcinomas. In Encyclopedia. https://encyclopedia.pub/entry/8255
Huang, Yen-Hua. "Hepatocellular Carcinomas." Encyclopedia. Web. 25 March, 2021.
Hepatocellular Carcinomas
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms22041931

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia.

insulin-like growth factor liver cancer cancer stemness

1. Introduction

Hepatocellular carcinoma (HCC) accounts for about 75–85% of all primary liver cancer [1][2], which is one of the top five causes of cancer deaths worldwide [2]. HCC can develop from loss of cell cycle control in adult hepatocytes or progenitor cells. Several risk factors for developing HCC have been identified, including hepatitis virus infection, abnormal fatty acid metabolism, alcoholic liver disease, and toxins [1][3][4]. The dominant cause varies across different geographical areas [5].

In five main types of hepatitis virus (type A, B, C, D, and E), types B and C cause the most public health burden, as they are responsible for more than half number of HCC [6]. Moreover, according to an investigation on the global burden of viral hepatitis from 1990 to 2013, about 96% of the viral hepatitis-related mortality are caused by hepatitis B and C [7]. In 2015, around 257 million people had chronic hepatitis B virus (HBV) infection, and 71 million had hepatitis C virus (HCV) infection [8]. A goal of the World Health Organization’s Global Strategy for Viral Hepatitis Elimination in 2016 was to reduce hepatitis-related deaths by 65% by 2030 (from 1.34 million deaths annually to less than 0.5 million) [9].

Therapeutic strategies available for HCC, such as resection, transplantation, ablation, radiotherapy, chemotherapy, and molecular targeting therapy, are highly dependent on the stage of liver cirrhosis and on the offerings of the medical center, which varies among different countries [1][3][4][10]. Targeted therapies (sorafenib and lenvatinib) have been approved for patients with advanced HCC who are not eligible for local treatments. However, the median overall survival (OS) with either sorafenib or lenvatinib is only about 13 months [11][12][13]. Therefore, an improvement for targeted therapies is needed.

2. The Etiology of HCC

2.1. Virus Infections Initiate HCC

HCC is often associated with HBV and HCV. According to a 2016 report by the U.S. Centers for Disease Control and Prevention, approximately 65% of liver cancers are associated with the hepatitis B or C virus. In a study of 3843 patients in Taiwan, hepatitis viruses were associated with more than 80% of HCC [6].

HBV is a small DNA virus with a partially double-stranded DNA of 3200 bp [14]. HBV infection is responsible for 66% of virus-caused HCC deaths worldwide [8]. The highest prevalence of HBV infection is reported in the African (6.1%) and Western Pacific (6.2%) regions [8]. Most cases of HBV are transmitted through bodily fluids, such as via blood transfusion, sexual contact, or from mother to child. The HBV virus can amplify independently inside hepatocytes; integration of HBV into the hepatocyte genome can increase carcinogenic opportunities in HBV-infected patients.

The HBx gene is mainly responsible for HBV-associated HCC development. The HBV DNA contains four open reading frames (ORFs), which code for surface antigen (S) protein, precore (C) protein, polymerase (P) protein, and X proteins [15][16]. The ORF-X is the smallest ORF with 462 bp, and it acts as a viral production promotor within the cell [17][18]. Silencing the X gene results in the suppression of HBeAg production and viral production [19][20]. HBx exerts its effects on cell cycle progression and the normal physiology of hepatocytes by upregulating levels of G1 proteins [21]. In addition, HBx initiates HCC development by upregulating Ras/Raf/MAPK signaling, PI-3K/Akt signaling, Jak/STAT signaling, and NFκB signaling [16][22].

HBV perinatal transmission is more effective because the immune systems have not fully matured yet in fetus [23]. Acquisition of HBV in the early life causes chronic infection in most cases while infection in adults is usually recovered with subsequent acquired immunity [24][25][26]. A study of 1280 seronegative patients from 12 Yupik Eskimo villages in America demonstrated that the rate of chronic hepatitis B in HBV infected patients declined with increasing age. Percentages for the ≤4 years group, 5–9 years group, and adults (>30 years) group were 28%, 16.4%, and 7.7%, respectively [25]. Fortunately, there is a vaccine to prevent HBV infection that is effective for all ages including infants, children, and adults [8].

The HCV pandemic affects all regions worldwide; the highest prevalence occurred in Central Asia, East Europe, and central and Western Saharan of Africa [8][27]. Globally, there were 1.75 million new HCV infections and 57 million people living with chronic HCV in 2015 [8]. Approximately, 75% of patients with acute HCV infection progress to develop chronic HCV, and the risk of developing cirrhosis/HCC from chronic HCV is approximately 10–20% [28][29].

Unlike HBV, HCV is an RNA virus, which makes it difficult to insert into the hepatocyte genome. Therefore, its carcinogenic activity is linked to indirect mechanisms. The HCV relies on endoplasmic reticulum (ER) in the hepatocyte to produce viral proteins, thus causing the ER stress. The ER is an important organelle that helps to maintain normal functions of hepatocytes, such as the transportation of proteins and lipids and the synthesis of proteins [30][31][32]. As a result, injuring hepatocytes by HCV could lead to cirrhosis.

There is no effective HCV vaccine; however, effective HCV therapies are available and work well. Direct-acting antivirus (DAA) therapy was introduced in 2013 and became recommended first line treatment for HCV by WHO guidelines in 2014 [8]. DAA therapy can cure 95% of HCV infections [29].

Coinfection with both virus types raises the risk for cirrhosis progression [33][34], and cirrhosis progression is highly possible to lead to HCC initiation. Coinfected patients show a higher rate of cirrhosis than HBV mono-infected patients (44% vs. 21%) [35]. In addition, the percentage of cirrhosis and HCC in dual-infected patients is higher than in HCV mono-infected patients (95% vs. 48.5 and 63% vs. 15%, respectively) [36]. Coinfected patients were more often immigrants from Africa and Asia than HCV- or HBV-mono-infected patients (52% vs. 20% and 22%, respectively, p = 0.01) [34]. In addition, 2.7 million patients are coinfected with HBV-HIV and 2.3 million patients are coinfected with HCV-HIV [8]. Coinfection with HBV/HCV and HIV raises the risk of liver cirrhosis and HCC development [37][38][39]. The liver-related mortality rate of patients with HBV-HIV (14.2/1000) is higher than that of patients with only HIV (1.7/1000) or only HBV (0.8/1000) [37].

2.2. Obesity and NAFLD Cause HCC

Obesity is rapidly becoming a health problem all over the world, especially in Western countries. It is established that more than 2 billion people are overweight or obese worldwide. By the year 2030, it is projected that 38% of adults will be overweight and 20% will be obese if this trend is not changed [40]. It is well known that obesity is highly associated with other health problems such as cardiovascular disease, stroke, hypertension, and cancer. A meta-analysis of data from 1,779,471 individuals from articles published from 1996 to 2011 found a positive correlation between body mass index (BMI) and risk of liver cancer. Persons with a BMI of 25, 30, or 35 kg/m2 had a 1.02, 1.35, or 2.22 fold relative risk of liver cancer, respectively [41]. In a retrospective analysis of 714 patients with HCC who underwent curative hepatectomy, the 5-year OS rate of HBV-HCC patients with BMI ≥ 25 kg/m2 (65%) was lower than that of HBV-HCC patients with BMI < 25 kg/m2 (85%). However, among patients with HCV-HCC, those with BMI ≥ 25 kg/m2 had a better 5-year OS rate than those with BMI < 25 kg/m2 (75% vs. 65%) [42].

Recently, nonalcoholic steatohepatitis (NAFLD), which is caused by obesity and some hepatic histological damage, became the major cause of chronic liver disease in Western countries [43]. The risk of HCC developing in nonalcoholic steatohepatitis (NASH)-associated cirrhosis was 2.4–12.8% while that of HCC developing in NASH without cirrhosis was low (0–3%) [44]. Besides, a study, which compared 296,707 patients with NAFLD with 296,707 matched control, showed that the HCC incidence was significantly higher among NAFLD patients versus control (0.02/1000 person-years; hazard ratio, 7.62, 95% confidence interval = 5.76–10.09) [45]. Similarly, a data analysis from four databases which included 18,782,281 eligible individuals from United Kingdom, Netherlands, Italy, and Spain showed that patients with NAFLD/NASH had cirrhosis risk and HCC risk significantly higher than controls with pooled hazard ratios 4.73 (95% CI 2.43–9.19) and 3.51 (95% CI 1.72–7.16), respectively [46]. The data of 25,947 subjects in Korea from September 1, 2004, to December 31, 2005, indicated the NAFLD was associated with the development of HCC. The cancer incidence rate of patients with NAFLD was significantly higher than that of control (782.9 version 592.8/100,000 person-years; hazard ratio 1.32; 95%CI 2.09–133.85; p < 0.001) [47].

Furthermore, the risk of NAFLD-related HCC increased quickly in the last two decades. A study that included 323 HCC patients from 1995–1999 to 2010–2014, indicated that the prevalence of NAFLD-HCC increased from 2.6% to 19.5%, respectively, p = 0.003 [48]. In addition, among 158,347 adult liver transplant candidates in United State, the proportion of patients with HCC increased from 6.4% (2002) to 23% (2016) (trend p < 0.001) [49].

Together, these data suggest that the risk of HCC due to NAFLD is going more serious while that of HCC due to HCV/HBV infection is going better of control. However, until recently, there is no consensus on optimal HCC screening measures for patients with NAFLD/NASH.

2.3. Other Factors That Cause HCC

Aflatoxins, a group of mycotoxins produced by the fungi Aspergillus flavus and Aspergillus parasiticus, account for a large part of toxin-related HCC. People in tropical countries may ingest aflatoxin through fungal-contaminated food that was improperly stored in high humidity and temperature. Aflatoxin causes an arginine–to-serine mutation at codon 249 of the p53 gene, leading to cancellation of the tumor suppression functions of this gene. A study using HCC samples from high and low risk areas of aflatoxin showed that the third nucleotide guanine to thymine transversion mutation at codon 249 was present in 57% and 10% of samples, respectively [50]. Similarly, liver cancer cell lines that were induced to express high levels of CYP450 were more sensitive to the cytotoxic effect of aflatoxin than parental cells. The third nucleotide guanine to thymine transversions in the codon number 249 and the first nucleotide cytosine to adenine transversions at codon number 250 of p53 gene were found at a high frequency [51]. A high incidence of HCC is found in areas where aflatoxin and HBV infection are common, raising speculation regarding a synergic carcinogenic interaction between aflatoxin and HBV infection [52]. A study on HCC samples from Guangxi, China, confirmed the positive correlation between HCC and aflatoxin but evidence for an HBV-aflatoxin interaction modulating the p53 mutation [53] or for a hepatitis B surface antigen (HBsAg) and aflatoxin synergistic effect in HCC [54] was not clear.

Alcohol consumption, another risk factor for HCC, induces liver cancer development through steatosis, steatohepatitis, and cirrhosis. The acetaldehyde and lipid peroxidation from ethanol metabolism in the liver creates protein adducts and DNA adducts, which can trigger liver injury and fibrogenesis [55][56][57]. In addition, alcohol metabolism-derived ROS can destroy large organelles and alter the structure and function of DNA [58]. Oxidative stress in the liver promotes the secretion of cytokines and chemokines (IL-6, IL10, IL1β, and TNFα) [59][60][61][62] and activates several signaling pathways (Jak/STAT; NF-kB, and MAPK cascade) which are implicated in the initiation of HCC. Findings from a systematic review and meta-analysis indicate that the relative risks of liver cancer for moderate drinking (<3 drinks/day) and heavy drinking (≥3 drinks/day) are 0.91 and 1.16, in comparison to non-drinking. The study also found an estimated excess risk of 46% or 66% in drinkers who consumed 50 g or 100 g alcohol per day [63]. A projected prevalence study has predicted that, if current trends continue, deaths due to alcohol-related liver disease will increase from 8.23 deaths/100,000 person-years in 2019 to 15.20 deaths/100,000 person-years in 2040 [64].

References

  1. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236.
  2. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
  3. Fujiwara, N.; Friedman, S.L.; Goossens, N.; Hoshida, Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J. Hepatol. 2018, 68, 526–549.
  4. Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 2019, 380, 1450–1462.
  5. Mak, L.-Y.; Cruz-Ramón, V.; Chinchilla-López, P.; Torres, H.A.; LoConte, N.K.; Rice, J.P.; Foxhall, L.E.; Sturgis, E.M.; Merrill, J.K.; Bailey, H.H.; et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 262–279.
  6. Chang, I.C.; Huang, S.F.; Chen, P.J.; Chen, C.L.; Chen, C.L.; Wu, C.C.; Tsai, C.C.; Lee, P.H.; Chen, M.F.; Lee, C.M.; et al. The hepatitis viral status in patients with hepatocellular carcinoma: A study of 3843 patients from taiwan liver cancer network. Medicine 2016, 95, e3284.
  7. Stanaway, J.D.; Flaxman, A.D.; Naghavi, M.; Fitzmaurice, C.; Vos, T.; Abubakar, I.; Abu-Raddad, L.J.; Assadi, R.; Bhala, N.; Cowie, B.; et al. The global burden of viral hepatitis from 1990 to 2013: Findings from the global burden of disease study 2013. Lancet 2016, 388, 1081–1088.
  8. World-Health-Organization. Global Hepatitis Report, 2017; WHO: Geneva, Switzerland, 2017.
  9. World-Health-Organization. Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis; WHO: Geneva, Switzerland, 2016.
  10. Yang, J.D.; Hainaut, P.; Gores, G.J.; Amadou, A.; Plymoth, A.; Roberts, L.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 589–604.
  11. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378–390.
  12. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25–34.
  13. Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018, 391, 1163–1173.
  14. Valaydon, Z.S.; Locarnini, S.A. The virological aspects of hepatitis b. Best Pract. Res. Clin. Gastroenterol. 2017, 31, 257–264.
  15. Colgrove, R.; Simon, G.; Ganem, D. Transcriptional activation of homologous and heterologous genes by the hepatitis b virus x gene product in cells permissive for viral replication. J. Virol. 1989, 63, 4019–4026.
  16. Zhang, X.; Zhang, H.; Ye, L. Effects of hepatitis b virus x protein on the development of liver cancer. J. Lab. Clin. Med. 2006, 147, 58–66.
  17. Weil, R.; Sirma, H.; Giannini, C.; Kremsdorf, D.; Bessia, C.; Dargemont, C.; Bréchot, C.; Israël, A. Direct association and nuclear import of the hepatitis b virus x protein with the nf-κb inhibitor iκbα. Mol. Cell. Biol. 1999, 19, 6345.
  18. Forgues, M.; Marrogi, A.J.; Spillare, E.A.; Wu, C.G.; Yang, Q.; Yoshida, M.; Wang, X.W. Interaction of the hepatitis b virus x protein with the crm1-dependent nuclear export pathway. J. Biol. Chem. 2001, 276, 22797–22803.
  19. Kidd-Ljunggren, K.; Oberg, M.; Kidd, A.H. Hepatitis b virus x gene 1751 to 1764 mutations: Implications for hbeag status and disease. J. Gen. Virol. 1997, 78, 1469–1478.
  20. Feitelson, M.A.; Duan, L.-X.; Guo, J.; Sun, B.; Woo, J.; Steensma, K.; Horiike, N.; Blumberg, B.S. X region deletion variants of hepatitis b virus in surface antigen-negative infections and non-a, non-b hepatitis. J. Infect. Dis. 1995, 172, 713–722.
  21. Gearhart, T.L.; Bouchard, M.J. The hepatitis b virus x protein modulates hepatocyte proliferation pathways to stimulate viral replication. J. Virol. 2010, 84, 2675.
  22. Ayub, A.; Ashfaq, U.A.; Haque, A. Hbv induced hcc: Major risk factors from genetic to molecular level. Biomed. Res. Int. 2013, 2013, 810461.
  23. Tsai, K.-N.; Kuo, C.-F.; Ou, J.-H.J. Mechanisms of hepatitis b virus persistence. Trends Microbiol. 2018, 26, 33–42.
  24. Umar, M.; Hamama Tul, B.; Umar, S.; Khan, H.A. Hbv perinatal transmission. Int. J. Hepatol. 2013, 2013, 875791.
  25. McMahon, B.J.; Alward, W.L.; Hall, D.B.; Heyward, W.L.; Bender, T.R.; Francis, D.P.; Maynard, J.E. Acute hepatitis b virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis. 1985, 151, 599–603.
  26. Tassopoulos, N.C.; Papaevangelou, G.J.; Sjogren, M.H.; Roumeliotou-Karayannis, A.; Gerin, J.L.; Purcell, R.H. Natural history of acute hepatitis b surface antigen-positive hepatitis in greek adults. Gastroenterology 1987, 92, 1844–1850.
  27. Blach, S.; Zeuzem, S.; Manns, M.; Altraif, I.; Duberg, A.-S.; Muljono, D.H.; Waked, I.; Alavian, S.M.; Lee, M.-H.; Negro, F.; et al. Global prevalence and genotype distribution of hepatitis c virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol. 2017, 2, 161–176.
  28. Hajarizadeh, B.; Grebely, J.; Dore, G.J. Epidemiology and natural history of hcv infection. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 553–562.
  29. Heffernan, A.; Cooke, G.S.; Nayagam, S.; Thursz, M.; Hallett, T.B. Scaling up prevention and treatment towards the elimination of hepatitis c: A global mathematical model. Lancet 2019, 393, 1319–1329.
  30. Wang, M.; Kaufman, R.J. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 2016, 529, 326–335.
  31. Vescovo, T.; Refolo, G.; Vitagliano, G.; Fimia, G.M.; Piacentini, M. Molecular mechanisms of hepatitis c virus–induced hepatocellular carcinoma. Clin. Microbiol. Infect. 2016, 22, 853–861.
  32. Dash, S.; Aydin, Y.; Widmer, K.E.; Nayak, L. Hepatocellular carcinoma mechanisms associated with chronic hcv infection and the impact of direct-acting antiviral treatment. J. Hepatocell. Carcinoma 2020, 7, 45–76.
  33. Liu, C.J.; Chu, Y.T.; Shau, W.Y.; Kuo, R.N.; Chen, P.J.; Lai, M.S. Treatment of patients with dual hepatitis c and b by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2014, 63, 506–514.
  34. Marot, A.; Belaid, A.; Orlent, H.; Sersté, T.; Michielsen, P.; Colle, I.; Laleman, W.; de Galocsy, C.; Reynaert, H.; D’Heygere, F.; et al. Characteristics of patients with hepatitis b virus and hepatitis c virus dual infection in a western european country: Comparison with monoinfected patients. Clin. Res. Hepatol. Gastroenterol. 2017, 41, 656–663.
  35. Fong, T.L.; Di Bisceglie, A.M.; Waggoner, J.G.; Waggoner, J.G.; Banks, S.M.; Hoofnagle, J.H. The significance of antibody to hepatitis c virus in patients with chronic hepatitis b. Hepatology 1991, 14, 64–67.
  36. Al Karawi, M.A.; Mesa, G.A. Dual infection with hepatitis c and b viruses: Clinical and histological study in saudi patients. Hepatogastroenterology 1997, 44, 1404–1406.
  37. Thio, C.L.; Seaberg, E.C.; Skolasky, R.; Phair, J.; Visscher, B.; Muñoz, A.; Thomas, D.L. Hiv-1, hepatitis b virus, and risk of liver-related mortality in the multicenter cohort study (macs). Lancet 2002, 360, 1921–1926.
  38. Soriano, V.; Vispo, E.; Labarga, P.; Medrano, J.; Barreiro, P. Viral hepatitis and hiv co-infection. Antiviral Res. 2010, 85, 303–315.
  39. Maier, I.; Wu, G.Y. Hepatitis c and hiv co-infection: A review. World J. Gastroenterol. 2002, 8, 577–579.
  40. Smith, K.B.; Smith, M.S. Obesity statistics. Prim. Care 2016, 43, 121–135, ix.
  41. Rui, R.; Lou, J.; Zou, L.; Zhong, R.; Wang, J.; Xia, D.; Wang, Q.; Li, H.; Wu, J.; Lu, X.; et al. Excess body mass index and risk of liver cancer: A nonlinear dose-response meta-analysis of prospective studies. PLoS ONE 2012, 7, e44522.
  42. Hashimoto, M.; Tashiro, H.; Kobayashi, T.; Kuroda, S.; Hamaoka, M.; Ohdan, H. Influence of higher bmi for hepatitis b- and c-related hepatocellular carcinomas. Langenbecks Arch. Surg. 2017, 402, 745–755.
  43. Nugent, C.; Younossi, Z.M. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4, 432–441.
  44. White, D.L.; Kanwal, F.; El-Serag, H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 2012, 10, 1342–1359.
  45. Kanwal, F.; Kramer, J.R.; Mapakshi, S.; Natarajan, Y.; Chayanupatkul, M.; Richardson, P.A.; Li, L.; Desiderio, R.; Thrift, A.P.; Asch, S.M.; et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018, 155, 1828–1837.
  46. Alexander, M.; Loomis, A.K.; van der Lei, J.; Duarte-Salles, T.; Prieto-Alhambra, D.; Ansell, D.; Pasqua, A.; Lapi, F.; Rijnbeek, P.; Mosseveld, M.; et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed nafld: Real-world study of 18 million patients in four european cohorts. BMC Med. 2019, 17, 95.
  47. Kim, G.-A.; Lee, H.C.; Choe, J.; Kim, M.-J.; Lee, M.J.; Chang, H.-S.; Bae, I.Y.; Kim, H.-K.; An, J.; Shim, J.H.; et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J. Hepatol. 2018, 68, 140–146.
  48. Pais, R.; Fartoux, L.; Goumard, C.; Scatton, O.; Wendum, D.; Rosmorduc, O.; Ratziu, V. Temporal trends, clinical patterns and outcomes of nafld-related hcc in patients undergoing liver resection over a 20-year period. Aliment. Pharmacol. Ther. 2017, 46, 856–863.
  49. Younossi, Z.; Stepanova, M.; Ong, J.P.; Jacobson, I.M.; Bugianesi, E.; Duseja, A.; Eguchi, Y.; Wong, V.W.; Negro, F.; Yilmaz, Y.; et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin. Gastroenterol. Hepatol. 2019, 17, 748–755.
  50. Deng, Z.-L.; Ma, Y. Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma. World J. Gastroenterol. 1998, 4, 28–29.
  51. Macé, K.; Aguilar, F.; Wang, J.S.; Vautravers, P.; Gómez-Lechón, M.; Gonzalez, F.J.; Groopman, J.; Harris, C.C.; Pfeifer, A.M. Aflatoxin b1-induced DNA adduct formation and p53 mutations in cyp450-expressing human liver cell lines. Carcinogenesis 1997, 18, 1291–1297.
  52. Kew, M.C. Synergistic interaction between aflatoxin and hepatitis b virus in hepatocarcinogenesis. Liver Int. 2013, 23, 405–409.
  53. Stern, M.C.; Umbach, D.M.; Yu, M.C.; London, S.J.; Zhang, Z.-Q.; Taylor, J.A. Hepatitis b, aflatoxin b1, and p53 codon 249 mutation in hepatocellular carcinomas from guangxi, people’s republic of china, and a meta-analysis of existing studies. Cancer Epidemiol. Biomark. Prev. 2001, 10, 617.
  54. Chittmittrapap, S.; Chieochansin, T.; Chaiteerakij, R.; Treeprasertsuk, S.; Klaikaew, N.; Tangkijvanich, P.; Komolmit, P.; Poovorawan, Y. Prevalence of aflatoxin induced p53 mutation at codon 249 (r249s) in hepatocellular carcinoma patients with and without hepatitis b surface antigen (hbsag). Asian Pac. J. Cancer Prev. 2013, 14, 7675–7679.
  55. Niemelä, O.; Parkkila, S.; Pasanen, M.; Iimuro, Y.; Bradford, B.; Thurman, R.G. Early alcoholic liver injury: Formation of protein adducts with acetaldehyde and lipid peroxidation products, and expression of cyp2e1 and cyp3a. Alcohol Clin. Exp. Res. 1998, 22, 2118–2124.
  56. Tsukamoto, H.; Horne, W.; Kamimura, S.; Niemelä, O.; Parkkila, S.; Ylä-Herttuala, S.; Brittenham, G.M. Experimental liver cirrhosis induced by alcohol and iron. J. Clin. Investig. 1995, 96, 620–630.
  57. Ganne-Carrie, N.; Nahon, P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J. Hepatol. 2019, 70, 284–293.
  58. De Minicis, S.; Brenner, D.A. Oxidative stress in alcoholic liver disease: Role of nadph oxidase complex. J. Gastroenterol. Hepatol. 2008, 23 (Suppl. S1), S98–S103.
  59. Zago, A.; Moreira, F.P.; Jansen, K.; Lhullier, A.C.; da Silva, R.A.; de Oliveira, J.F.; Medeiros, J.R.C.; Colpo, G.B.; Portela, L.V.; Lara, D.R.; et al. Alcohol use disorder and inflammatory cytokines in a population sample of young adults. Drug Alcohol Depend. 2016, 4, 2.
  60. Neupane, S.P.; Skulberg, A.; Skulberg, K.R.; Aass, H.C.D.; Bramness, J.G. Cytokine changes following acute ethanol intoxication in healthy men: A crossover study. Mediat. Inflamm. 2016, 2016, 3758590.
  61. Crews, F.T.; Bechara, R.; Brown, L.A.; Guidot, D.M.; Mandrekar, P.; Oak, S.; Qin, L.; Szabo, G.; Wheeler, M.; Zou, J. Cytokines and alcohol. Alcohol Clin. Exp. Res. 2006, 30, 720–730.
  62. An, L.; Wang, X.; Cederbaum, A.I. Cytokines in alcoholic liver disease. Arch. Toxicol. 2012, 86, 1337–1348.
  63. Turati, F.; Galeone, C.; Rota, M.; Pelucchi, C.; Negri, E.; Bagnardi, V.; Corrao, G.; Boffetta, P.; La Vecchia, C. Alcohol and liver cancer: A systematic review and meta-analysis of prospective studies. Ann. Oncol. 2014, 25, 1526–1535.
  64. Julien, J.; Ayer, T.; Bethea, E.D.; Tapper, E.B.; Chhatwal, J. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019–2040: A modelling study. Lancet Public Health 2020, 5, e316–e323.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cell Biology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Yen-Hua Huang
View Times: 276
Revisions: 2 times (View History)
Update Date: 25 Mar 2021
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback